Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientifi...(olerability and pharmacokinetics of oral...),Health

-- May 16-21, 2008: Positive Results from Phase 2 Clinical Trials for NKTR-061 (inhaled amikacin) to be presented at the American Thoracic Society (ATS) Meeting in Toronto, Canada:

Poster #516: "NKTR-061 (inhaled amikacin) BID achieves high

epithelial lining fluid concentrations in pneumonic portions of

lung"

Poster #517: "Evidence of High Amikacin Lung Deposition in

Mechanically Ventilated Patients (MVP) with Pneumonia and Healthy

Subjects (HS) dosed using NKTR-061"

Poster #518: "High in vivo amikacin lung deposition after NKTR-061

dosing correlates with in vitro aerosol characterization"

-- Positive Phase 1 Clinical data for NKTR-102 (PEG-irinotecan) will also be published at additional oncology conferences this year.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding upcoming presentations of preclinical and clinical results at medical and scientific meetings and the potential of Nektar's development technology platforms and product pipeline. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) Nektar's proprietary product candidates and those of certain of its partners are in the earl
'/>"/>